Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-01-18
2010-11-02
Bowman, Amy (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S320100, C536S023100, C536S024500
Reexamination Certificate
active
07825099
ABSTRACT:
The invention relates to one or more inhibitors, in particular siRNAs, which down-regulate the expression of human pro-apoptotic genes. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating or preventing the incidence or severity of hearing impairment (or balance impairment), particularly hearing impairment associated with cell death of the inner ear hair cells or outer ear hair cells, comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient.
REFERENCES:
patent: 4497817 (1985-02-01), Murase et al.
patent: 5898031 (1999-04-01), Crooke
patent: 6107094 (2000-08-01), Crooke
patent: 6372249 (2002-04-01), Smith et al.
patent: 6506559 (2003-01-01), Fire et al.
patent: 6593353 (2003-07-01), Gudkov et al.
patent: 2002/0019425 (2002-02-01), Gudkov et al.
patent: 2004/0180351 (2004-09-01), Giese et al.
patent: 2005/0080246 (2005-04-01), Allerson et al.
patent: 2006/0069056 (2006-03-01), Feinstein et al.
patent: 2006/0217329 (2006-09-01), Feinstein
patent: 2007/0031844 (2007-02-01), Khvorova et al.
patent: 2007/0185047 (2007-08-01), Bhat et al.
patent: 0430334 (1991-06-01), None
patent: WO 00/44895 (2000-08-01), None
patent: WO 01/36646 (2001-05-01), None
patent: WO 01/75164 (2001-10-01), None
patent: WO 02/44321 (2002-06-01), None
patent: WO 02/055693 (2002-07-01), None
patent: WO 03/070918 (2003-08-01), None
patent: WO 03/074654 (2003-09-01), None
patent: WO 2004/015107 (2004-02-01), None
patent: WO 2004/031237 (2004-04-01), None
patent: WO 2004/045543 (2004-06-01), None
patent: WO 2006/035434 (2006-04-01), None
Scherer et al., Approaches for the sequence-specific knockdown of mRNA, 2003, Nat. Biotechnol., 21(12), pp. 1457-1465.
Mahato et al., Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA, Jan. 2005, Expert Opinion on Drug Delivery, vol. 2, No. 1, pp. 3-28.
Zhang et al., Targeted Gene Silencing by Small Interfering RNA-Based Knock-Down Technology, 2004, Current Pharmaceutical Biotechnology, vol. 5, p. 1-7.
Zhang et al., Pifithrin-α Supresses p53 and Protects Cochlear and Vestibular Hair Cells From Cisplatin-Induced Apoptosis, 2003, Neuroscience, 120, pp. 191-205.
Schomber et al., Gene silencing by lentivirus-mediated delivery of siRNA in human CD34+ cells, 2004, Blood, vol. 103, No. 12, pp. 4511-4513.
Bertrand et al., Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo, 2002, Biochemical and Biophysical Research Communications, 296, pp. 1000-1004.
Elbashir et al., Functional anatomy of siRNAs for mediating efficienct RNAi inDrosophila melanogasterembryo lysate, 2001, The EMBO Journal, vol. 20, No. 23, pp. 6877-6888.
Holen et al., Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor, 2002, Nucleic Acids Research, vol. 30, No. 8, pp. 1757-1766.
Bartel, D.P., (2004) MicroRNAs: Genomics, Biogenesis, Mechanism, and Function. Cell 116:281-297.
Bernstein, E., et al., (2001) Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409:363-366.
Botchkarev, V.A., et al., (2000) p53 Is Essential for Chemotherapy-induced Hair Loss. Cancer Res. 60:5002-5006.
Brummelkamp, T.R., et al., (2002) A System for Stable Expression of Short Interfering RNAs in Mammalian Cells. Science 296:550-553.
Caplen, N.J., et al., (2001) Specific inhibition of gene expression by small-stranded RNAs in invertebrate and vertebrate systems. Proc. Natl. Acad. Sci. USA 98(17):9742-47.
Chalk, A.M., et al., (2004) Improved and automated prediction of effective siRNA. Biochem. Biophys. Res. Commun. 319:264-274.
Chernov, M.V. and Stark, G.R., (1997) The p53 activation and apoptosis induced by DNA damage are reversibly inhibited by salicylate. Oncogene 14:2503-2510.
Cotsarelis, G. and Millar, S.E., (2001) Towards a molecular understanding of hair loss and its treatment. Trends Mol. Med. 7(7):293-301.
Elbashir, S.M., et al., (2001) RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 15:188-200.
Elbashir, S.M., et al., (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494-498.
Fire, A., et al., (1998) Potent and specific genetic interference by double-stranded RNA inCaenorhabditis elegans.Nature 391:806-811.
Gottlieb, T.M., et al., (1996) p53 in growth control and neoplasia. Biochim Biophys Acta 1287:77-102.
Komarov, P.G., et al., (1999) A Chemical Inhibitor of p53 That Protects Mice from the Side Effects of Cancer Therapy. Science 285:1733-1737.
Komarova, E.A., et al., (1997) Transgenic mice with p53-responsivelacZ:p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo.EMBO J.16(6):1391-1400.
Levenkova, N., et al., (2004) Gene specific siRNA selector. Bioinformatics 20 (3):430-432.
McManus, M.T. and Sharp, P.A., (2002) Gene Silencing in Mammals by Small Interfering RNAs. Nature Rev. Genet. 3:737-747.
Sioud, M. and Leirdal, M., (2004) Potential design rules and enzymatic synthesis of siRNAs. Methods Mol. Biol. 252:457-469.
Steele, R.J.C., et al., (1998) The p53 tumour suppressor gene. Br. J. Surg. 85:1460-1467.
Supavekin, S., et al., (2003) Differential gene expression following early renal ischemia/reperfusion. Kidney Int. 63:1714-1724.
Tolentino, M.J., et al.,(2004) Intravitreal Injection of Vascular Endothelial Growth Factor Small Interfering RNA Inhibits Growth and Leakage in a Nonhuman Primate, Laser-induced Model of Choroidal Neovascularization.Retina24:132-138.
Ui-Tei, K., et al., (2004) Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. Nucleic Acids Res. 32(3):936-948.
TeKippe, M., et al., (2003) Expansion of hematopoietic stem cell phenotype and activity in Trp53-null mice. Exp. Hematol. 31:521-527.
Wlodarski, P., et al., (1998) Role of p53 in Hematopoietic Recovery After Cytotoxic Treatment. Blood 91(8):2998-3006.
Elena Feinstein, et al., U.S. Appl. No. 11/827,199, filed Jul. 10, 2007.
Pending claims in Elena Feinstein, et al., U.S. Appl. No. 11/827,199, filed Jul. 10, 2007.
Office Action issued on Nov. 7, 2006 in connection with U.S. Appl. No. 11/237,598, filed Sep. 27, 2005.
Response to Nov. 7, 2006 Office Action in connection with U.S. Appl. No. 11/237,598, filed Dec. 12, 2006.
Office Action issued on Mar. 14, 2007 in connection with U.S. Appl. No. 11/237,598, filed Sep. 27, 2005.
Response to Mar. 14, 2007 Office Action in connection with U.S. Appl. No. 11/237,598, filed Dec. 12, 2006.
Final Office Action issued on Dec. 3, 2007 in connection with U.S. Appl. No. 11/237,598, filed Sep. 27, 2005.
Elena Feinstein, et al., U.S. Appl. No. 12/008,578, filed Jan. 11, 2008 (Exhibit 36).
Pending claims in Elena Feinstein, et al., U.S. Appl. No. 11/827,199, filed Jan. 11, 2008.
Bark, Sailen (2005). “Silence of the Transcripts; RNA Interference In Medicine,” J. Mol. Med. 83:764-773.
Bitko, Vira et al. (2004). “Inhibition of Respiratory Viruses By Nasally Administered siRNA,” Nature Medicine, 11(1):50-55.
Chakraborty, Chrianjib (2007). “Potentially of Small Interfering RNAs (siRNA) as Recent Therapeutic Targets for Gene-Silencing,” Current Drug Targets, 8:469-482.
Lee, Youngjae et al., (2003). “The nuclear RNase III Drosha initiates microRNA processing,” Nature, 425:415-419.
Wang, J. et al. (2003). “A Peptide Inhibitor of c-Jun N-Terminal Kinase Protects against Both Aminoglycoside and Acoustic . . . ,” The J. of Neuroscience, 23(24):8596-8607.
Zhang, M. et al., (2003). “Pifithrin-α Supresses p53 and Protects Cochlear and Vestibular Hair Cells From Cisplatin-Induced Apoptosis,” Neuroscience, 120:191-205.
Mar. 14, 2007 Non-final Office Action issued in connection with U.S. Appl. No. 11/237,598.
Dec. 3, 2007 Final Office Action issued in
Bowman Amy
Cooper & Dunham LLP
Quark Pharmaceuticals Inc.
White John P.
LandOfFree
Treatment or prevention of oto-pathologies by inhibition of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment or prevention of oto-pathologies by inhibition of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment or prevention of oto-pathologies by inhibition of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4216063